NEJM:MRI用于高乳腺组织密度人群乳腺癌的辅助筛查

2019-11-29 MedSci MedSci原创

研究认为,对乳腺组织密度极高的妇女在X线检查基础上进行MRI辅助筛查可显著较低筛查间隔期乳腺癌发病率

乳腺组织密度过大限制乳腺肿瘤的筛查。近日研究人员考察了磁共振成像(MRI)对改善乳腺组织密度过大人群早期乳腺发现和减少间隔期乳腺癌发病率的效果。

40373名年龄在50-75岁之间、乳腺组织密度极高、乳腺钼靶筛查结果正常的妇女分为受邀接受补充MRI检查或仅接受乳房X线摄影筛查,MRI组包含8061例,单纯X线组32312例。研究的主要结果是在2年的筛查期内,组间间期癌的发病率差异。

研究发现,MRI邀请组的间隔期癌症发生率为2.5/1000, X线照相组为5.0/1000,差异有显著性。受邀接受MRI检查的妇女中,59%的妇女接受了邀请。MRI组20例间隔癌患者中,4例为实际接受了MRI检查的妇女(0.8/1000次筛查),16例为未接受邀请的妇女(4.9次/1000次)。在实际接受MRI筛查的妇女中,MRI肿瘤检出率为16.5/1000次。MRI阳性预测值为17.4%,活检率26.3%,假阳性率为79.8/1000筛查。在接受MRI检查的妇女中,0.1%在筛查期间或之后发生不良事件或严重不良事件。

研究认为,对乳腺组织密度极高的妇女在X线检查基础上进行MRI辅助筛查可显著较低筛查间隔期乳腺癌发病率。

原始出处:

Marije F. Bakker et al. Supplemental MRI Screening for Women with Extremely Dense Breast Tissue. N Engl J Med, November 28, 2019.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1804852, encodeId=a81018048527a, content=<a href='/topic/show?id=8f66e768963' target=_blank style='color:#2F92EE;'>#组织密度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77689, encryptionId=8f66e768963, topicName=组织密度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5bc315, createdName=Tommy1949, createdTime=Mon Apr 20 02:38:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376023, encodeId=60743e602394, content=时间成本太高, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Nov 30 16:44:11 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376017, encodeId=36ab3e601767, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Nov 30 08:23:38 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376005, encodeId=ca733e60059d, content=学习了很有用不錯, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Sat Nov 30 00:18:20 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376002, encodeId=a74a3e6002d8, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Fri Nov 29 23:26:03 CST 2019, time=2019-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035031, encodeId=631a1035031b1, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Fri Nov 29 22:38:00 CST 2019, time=2019-11-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1804852, encodeId=a81018048527a, content=<a href='/topic/show?id=8f66e768963' target=_blank style='color:#2F92EE;'>#组织密度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77689, encryptionId=8f66e768963, topicName=组织密度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5bc315, createdName=Tommy1949, createdTime=Mon Apr 20 02:38:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376023, encodeId=60743e602394, content=时间成本太高, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Nov 30 16:44:11 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376017, encodeId=36ab3e601767, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Nov 30 08:23:38 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376005, encodeId=ca733e60059d, content=学习了很有用不錯, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Sat Nov 30 00:18:20 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376002, encodeId=a74a3e6002d8, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Fri Nov 29 23:26:03 CST 2019, time=2019-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035031, encodeId=631a1035031b1, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Fri Nov 29 22:38:00 CST 2019, time=2019-11-29, status=1, ipAttribution=)]
    2019-11-30 lovetcm

    时间成本太高

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1804852, encodeId=a81018048527a, content=<a href='/topic/show?id=8f66e768963' target=_blank style='color:#2F92EE;'>#组织密度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77689, encryptionId=8f66e768963, topicName=组织密度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5bc315, createdName=Tommy1949, createdTime=Mon Apr 20 02:38:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376023, encodeId=60743e602394, content=时间成本太高, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Nov 30 16:44:11 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376017, encodeId=36ab3e601767, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Nov 30 08:23:38 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376005, encodeId=ca733e60059d, content=学习了很有用不錯, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Sat Nov 30 00:18:20 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376002, encodeId=a74a3e6002d8, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Fri Nov 29 23:26:03 CST 2019, time=2019-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035031, encodeId=631a1035031b1, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Fri Nov 29 22:38:00 CST 2019, time=2019-11-29, status=1, ipAttribution=)]
    2019-11-30 1ddf0692m34(暂无匿称)

    学习了,谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1804852, encodeId=a81018048527a, content=<a href='/topic/show?id=8f66e768963' target=_blank style='color:#2F92EE;'>#组织密度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77689, encryptionId=8f66e768963, topicName=组织密度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5bc315, createdName=Tommy1949, createdTime=Mon Apr 20 02:38:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376023, encodeId=60743e602394, content=时间成本太高, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Nov 30 16:44:11 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376017, encodeId=36ab3e601767, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Nov 30 08:23:38 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376005, encodeId=ca733e60059d, content=学习了很有用不錯, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Sat Nov 30 00:18:20 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376002, encodeId=a74a3e6002d8, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Fri Nov 29 23:26:03 CST 2019, time=2019-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035031, encodeId=631a1035031b1, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Fri Nov 29 22:38:00 CST 2019, time=2019-11-29, status=1, ipAttribution=)]
    2019-11-30 飛歌

    学习了很有用不錯

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1804852, encodeId=a81018048527a, content=<a href='/topic/show?id=8f66e768963' target=_blank style='color:#2F92EE;'>#组织密度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77689, encryptionId=8f66e768963, topicName=组织密度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5bc315, createdName=Tommy1949, createdTime=Mon Apr 20 02:38:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376023, encodeId=60743e602394, content=时间成本太高, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Nov 30 16:44:11 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376017, encodeId=36ab3e601767, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Nov 30 08:23:38 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376005, encodeId=ca733e60059d, content=学习了很有用不錯, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Sat Nov 30 00:18:20 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376002, encodeId=a74a3e6002d8, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Fri Nov 29 23:26:03 CST 2019, time=2019-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035031, encodeId=631a1035031b1, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Fri Nov 29 22:38:00 CST 2019, time=2019-11-29, status=1, ipAttribution=)]
    2019-11-29 qingfengqishi5

    学习了,学习了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1804852, encodeId=a81018048527a, content=<a href='/topic/show?id=8f66e768963' target=_blank style='color:#2F92EE;'>#组织密度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77689, encryptionId=8f66e768963, topicName=组织密度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5bc315, createdName=Tommy1949, createdTime=Mon Apr 20 02:38:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376023, encodeId=60743e602394, content=时间成本太高, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Nov 30 16:44:11 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376017, encodeId=36ab3e601767, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Nov 30 08:23:38 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376005, encodeId=ca733e60059d, content=学习了很有用不錯, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Sat Nov 30 00:18:20 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376002, encodeId=a74a3e6002d8, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Fri Nov 29 23:26:03 CST 2019, time=2019-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035031, encodeId=631a1035031b1, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Fri Nov 29 22:38:00 CST 2019, time=2019-11-29, status=1, ipAttribution=)]
    2019-11-29 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

相关资讯

新型乳腺癌化疗药物艾立布林获NMPA批准上市

卫材株式会社(总部位于日本东京,现任社长为内藤晴夫,以下简称“卫材”)宣布,中国国家药品监督管理局已批准卫材原研抗癌药甲磺酸艾立布林(海乐卫®)上市,用于治疗既往接受过至少两种化疗方案(包括蒽环类和紫杉类)治疗的局部复发或转移性乳腺癌患者。该批准基于3041研究的结果,一项多中心、开放性、随机、平行对照的III期临床研究,旨在评价艾立布林和长春瑞滨对530例局部复发或转移性乳腺癌女性患者的疗效

2019 ESMO亚洲大会:国产曲妥珠单抗仿制药HLX02治疗乳腺癌在全球III期试验达到了主要终点

2019年ESMO亚洲大会上,根据一项大型的随机III期研究报告,在人类表皮生长因子受体2阳性(HER2 +)复发或先前未治疗的转移性乳腺癌女性中,复宏汉霖开发的曲妥珠单抗生物仿制药HLX02达到了与曲妥珠单抗相似的总体缓解率。

JAMA Oncol:有乳腺癌家族史的女性进行乳腺癌筛查的起始年龄

乳腺癌筛查指南认为有必要对高危妇女进行早期筛查,但对有乳腺癌家族史的妇女提供的指导有限。明确对乳腺癌患者家属进行风险适应性筛查的起始年龄或可助于补充目前的筛查指南。研究人员为了明确有家族史的女性进行乳腺癌筛查的起始年龄,开展了一项全国性的队列研究。纳入1932年后出生的、至少有一位直系亲属(FDR)记录的女性。收集1958年1月1日-2015年12月31日期间的数据。共纳入5 099 172位女性

国内外周T细胞淋巴瘤原创药获批第二个适应症,这次是乳腺癌

日前,微芯生物西达本胺新适应症获批,用于联合内分泌疗法治疗ER+、HER2-、经既往内分泌治疗复发/转移的晚期乳腺癌患者,该适应症于2018年11月申报上市,2019年1月被纳入优先审评审批。

欧洲药品管理局CHMP建议批准7种药物上市和2种药物扩展适应症

欧洲药品管理局的人类用药产品委员会(CHMP)在11月的会议上,建议批准7种药物以及2种药物的扩展。

Science:PIK3CA双突变患者对PI3Kα抑制剂的敏感性增强

在人类乳腺癌中常见PIK3CA激活突变,该基因编码磷脂酰肌醇-3激酶的催化亚基。磷脂酰肌醇-3激酶α(PI3Kα)抑制剂已获得批准用于治疗这类癌症。评估PI3K抑制剂用于癌症患者的疗效的临床试验正在进行中。为明确影响这些药物敏感性的决定因素,研究人员对PIK3CA-突变型癌症的基因组进行分析,发现在12-15%的乳腺癌和其他肿瘤类型中,存在PIK3CA多重突变,大部分(95%)为双突变。双PIK3